Manufacturer of Controlled Substances; Notice of Application, 30167 [E6-7989]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 101 / Thursday, May 25, 2006 / Notices
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 17, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–7989 Filed 5–24–06; 8:45 am]
Dated: May 17, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–7982 Filed 5–24–06; 8:45 am]
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 24, 2006,
Stepan Company, Natural Products
Dept., 100 W. Hunter Avenue,
Maywood, New Jersey 07607, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedule I and II:
Schedule
cchase on PROD1PC60 with NOTICES
Cocaine (9041) .............................
Benzoylecgonine (9180) ...............
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customer.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than July 24, 2006.
VerDate Aug<31>2005
16:42 May 24, 2006
Jkt 208001
DEPARTMENT OF JUSTICE
Kevin Dean Brockbank, M.D.;
Revocation of Registration
BILLING CODE 4410–09–P
Drug
BILLING CODE 4410–09–P
On October 14, 2004, the Deputy
Administrator of the Drug Enforcement
Administration (DEA) issued an Order
to Show Cause and Immediate
Suspension of Registration to Kevin
Dean Brockbank, M.D. (Dr. Brockbank)
of Lakeside, Arizona. Dr. Brockbank was
notified of an opportunity to show cause
as to why DEA should not revoke his
DEA Certificate of Registration,
AB2053027, as a practitioner, and deny
any pending applications for renewal or
modification of that registration
pursuant to 21 U.S.C. 823(f) and
824(a)(4) on the basis that his continued
registration would be inconsistent with
the public interest. Dr. Brockbank was
further notified that pursuant to 21
U.S.C. 824(d), his DEA registration was
being immediately suspended as an
imminent danger to the public health
and safety.
The Order to Show Cause and
Immediate Suspension of Registration
alleged, in sum, that Dr. Brockbank was
issuing prescriptions for large amounts
of controlled substances to individuals
without physical examinations, testing
or evaluations consistent with a
legitimate doctor-patient relationship.
These prescriptions, which included
OxyContin and hydrocodone, were not
issued for legitimate medical purposes
or in the usual course of professional
treatment, thus violating 21 CFR
1306.04 and 21 U.S.C. 841(a). It was also
alleged that over a six month period in
2004, on six occasions Dr. Brockbank
issued prescriptions under such
circumstances to local law enforcement
officers posing undercover as patients.
The Order to Show Cause and
Immediate Suspension of Registration
alleged that over a 13 month period, Dr.
Brockbank prescribed an estimated
690,000 dosage units of controlled
substances to patients and that local
pharmacies were refusing to fill or
drastically reducing the ordered
amounts of medication he was
prescribing. As a result, individuals
were traveling long distances to fill their
prescriptions at out-of-area pharmacies.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
30167
It was also alleged that one individual
died of an accidental overdose of
Schedule II controlled substances,
which had been excessively prescribed
by Dr. Brockbank to a friend of the
victim and obtained by the decedent
while visiting. Finally, it was alleged Dr.
Brockbank had sexually assaulted a
female patient during a home visit after
administering her a Schedule II
controlled substance.
According to the investigative file, the
Order to Show Cause and Immediate
Suspension of Registration was
personally served on Dr. Brockbank by
a DEA Diversion Investigator on October
26, 2004. More than thirty days have
passed since service of the Order to
Show Cause and Immediate Suspension
of Registration and DEA has not
received a request for hearing or any
other reply from Dr. Brockbank or
anyone purporting to represent him in
this matter.
Therefore, the Deputy Administrator
of DEA, finding that (1) thirty days
having passed since the delivery of the
Order to Show Cause and Immediate
Suspension of Registration to Dr.
Brockbank, and (2) no request for
hearing having been received, concludes
that Dr. Brockbank is deemed to have
waived his hearing right. See David W.
Linder, 67 FR 12,579 (2002). After
considering material from the
investigation file in this matter, the
Deputy Administrator now enters her
final order without a hearing pursuant
to 21 CFR 1301.43(d) and (e) and
1301.46.
The Deputy Administrator finds that
Dr. Brockbank is currently registered
with DEA as a practitioner under DEA
Certificate of Registration AB2053027.
According to information in the
investigative file, on October 18, 2004,
Dr. Brockbank entered into a Consent
Agreement for Surrender of Active
License (Consent Agreement) with the
Arizona Medical Board. In that Consent
Agreement Dr. Brockbank admitted
prescribing narcotic medications to two
female patients without obtaining and
recording detailed patient and family
histories, performing minimum physical
examinations or informing the
individuals of the risks and benefits of
taking the controlled medications.
These actions were found to be outside
the standard of care for a physician
licensed to practice in Arizona. Dr.
Brockbank also admitted making ‘‘house
calls’’ to two female patients, where he
injected them with controlled
substances and then made sexual
comments and advances toward them.
The Arizona Board concluded Dr.
Brockbank had engaged in
unprofessional conduct under state law
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 71, Number 101 (Thursday, May 25, 2006)]
[Notices]
[Page 30167]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-7989]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 24, 2006, Stepan
Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New
Jersey 07607, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in Schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cocaine (9041)............................. II
Benzoylecgonine (9180)..................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customer.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than July 24, 2006.
Dated: May 17, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-7989 Filed 5-24-06; 8:45 am]
BILLING CODE 4410-09-P
